SCHEMBL4037432

SCHEMBL4037432

COc1ccc2cc(C)c(NC(=O)c3ccccc3NCc3ccc(Br)nc3)nc2c1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 4/20 0.44
MAPT P10636 2/20 0.43
TP53 P04637 1/20 0.43
FLT1 P17948 1/20 0.42
HPGDS O60760 3/20 0.42
KDM4E B2RXH2 1/20 0.39
ASPH Q12797 1/20 0.39
RIOX2 Q8IUF8 1/20 0.39
KDM8 Q8N371 1/20 0.39
HDAC1 Q13547 1/20 0.39
AURKA O14965 1/20 0.38
AURKB Q96GD4 1/20 0.38
CD38 P28907 1/20 0.38
HCAR2 Q8TDS4 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
ALDH1A1 P00352 1/20 0.38
POLB P06746 1/20 0.38
RAB9A P51151 1/20 0.38
TDP1 Q9NUW8 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4037145 0.90 KDM4E (0.48) KDRMAPTTP53FLT1HPGDS
SCHEMBL4037147 0.88 KDR (0.43) KDRMAPTTP53FLT1HPGDS
SCHEMBL6542888 0.88 KDR (0.43) KDRMAPTTP53FLT1HPGDS
SCHEMBL4032277 0.87 KDR (0.42) KDRMAPTTP53FLT1HPGDS
SCHEMBL4035003 0.82 KDR (0.45) KDRMAPTTP53FLT1HPGDS
SCHEMBL4035005 0.82 KDR (0.45) KDRMAPTTP53FLT1HPGDS
SCHEMBL4037293 0.82 KIT (0.51) KDRMAPTTP53FLT1HPGDS
SCHEMBL4037276 0.80 KDR (0.43) KDRMAPTTP53FLT1AURKA
SCHEMBL4037715 0.79 NPC1 (0.49) MAPTTP53KDM4EHDAC1ALDH1A1
SCHEMBL3864004 0.74 F10 (0.48) KDRFLT1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1392680-B1 SELECTIVE ANTHRANILAMIDE PYRIDINE AMIDES AS INHIBITORS OF VEGFR-2 AND VEGFR-3 BAYER SCHERING PHARMA AG (DE) 2009-07-22 EP disclosed
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2004-12-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040254185-A1 Selective anthranilamide pyridine amides as inhibitors of vegfr-2 and vegfr-3 FLT4, KDR, FLT1 KDR 2/4885MAPT 3362/4885TP53 784/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.